Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Business” or “Sona”), a nanotechnology business establishing pre-clinical Targeted Hyperthermia Treatment for colorectal cancer, is delighted to reveal the election as chair of the board, Mr. Mark Lievonen, CM, who signed up with the board of Sona in December 2020. Mr. Lievonen acted as president of Sanofi Pasteur Limited from 1999 to 2016, throughout which time it ended up being a billion-dollar business in Canada, producing over 50 million dosages of vaccines for both domestic and worldwide markets. A business director and principal of JML Advisory Providers, Mr. Lievonen likewise co-chairs Canada’s COVID-19 Vaccine Job Force.
Mr. Lievonen likewise serves on a variety of public business and not-for-profit boards, and as a consultant to other services and organizations. Mr. Lievonen prospers Mr. Jim Megann, principal of Numus Financial, who will continue to act as a director of Sona.
” I am delighted to handle this function at Sona as the Business moves towards pre-clinical research studies for its essential Targeted Hyperthermia Treatment, focusing initially on colorectal cancer. I’m stimulated by Sona’s work producing and putting together the pre-clinical research study information required to protect assistance from regulators for scientific trials and I anticipate totally contributing towards this objective.”
Likewise, as pondered in the Business’s March 2023 acquisition of Siva Rehab, Inc., Leonard Pagliaro, PhD, has actually been selected to Sona’s board of directors. Dr. Pagliaro has actually held senior R&D, organization advancement, and management positions for business consisting of Eurofins and ThermoFisher Scientific following his scholastic profession at the University of Washington and Carnegie Mellon University, and he holds a PhD in cell biology and biochemistry from Wesleyan University.
” We are lucky to have somebody with the life sciences qualifications and business achievements of Mark to enter the function of chair as Sona advances its advancement of a crucial sophisticated medical treatment. We continue to construct a winning group with the skillsets required to direct this advancement, consisting of the current engagement of a senior medical gadget item advancement specialist with substantial experience taking such items from beginning all the method to commercialization. We are likewise pleased to gain from the ongoing acumen of Jim Megann who has actually competently acted as chair given that 2019. On behalf of Sona, thank you to both Mark and Jim for their continuing contributions and welcome to Len Pagliaro, PhD.,” Sona’s CEO, David Regan, commented.
The Business is likewise pleased to reveal a very first territorial patent grant for its proprietary, toxin-free gold nanorod production procedure with a registration in South Korea. Patent applications for other significant markets are pending.
Contact:
David Regan, CEO
+1 -902 -536 -1932
[email protected]
About Sona Nanotech Inc.
Sona Nanotech is a nanotechnology life sciences company that has actually established numerous exclusive techniques for the manufacture of numerous kinds of gold nanoparticles. The primary organization performed and planned to be continued by Sona is the advancement and application of its exclusive innovations for usage in multiplex diagnostic screening platforms that will enhance efficiency over existing tests in the market. Sona Nanotech’s gold nanorod particles are cetyltrimethylammonium (” CTAB”) totally free, removing the toxicity threats related to using other gold nanorod innovations in medical applications. It is anticipated that Sona’s gold nanotechnologies might be adjusted for usage in applications, as a safe and reliable shipment system for numerous medical treatments, based on the approval of numerous regulative boards, consisting of Health Canada and the FDA.
CAUTIONARY DECLARATION REGARDING FORWARD-LOOKING INFO: This news release consists of specific “positive declarations” under suitable Canadian securities legislation, consisting of declarations the potential customers for the giving of patents and the effective advancement of sophisticated medical treatments. Positive declarations are always based upon a variety of presumptions or price quotes that, while thought about sensible, go through recognized and unidentified threats, unpredictabilities, and other elements which might trigger the real outcomes and future occasions to vary materially from those revealed or indicated by such positive declarations, consisting of the threat that Sona might not have the ability to effectively protect animal pre-clinical and human scientific research studies, acquire adequate scientific and other information to send regulative submissions, raise adequate extra capital or establish the imagined treatment. There can be no guarantee that such declarations will show to be precise, as real outcomes and future occasions might vary materially from those prepared for in such declarations. Appropriately, readers must not put unnecessary dependence on positive declarations. Sona disclaims any intent or commitment to upgrade or modify any positive declarations, whether as an outcome of brand-new info, future occasions or otherwise, other than as needed by law.